
http://perceptivenavigation.com/
Perceptive Navigation, LLC is a Maryland-based medical device company developing solutions for the rapidly growing image-guidance market. The company’s core technology provides for a forward-viewing, image-guided interventional system that seeks to significantly improve both the safety and efficacy of millions of procedures per year in the areas of cardiology, interventional radiology, interventional oncology, and emergency medicine. Perceptive’s first product, the Vu-PathTM Ultrasound Guidance System, will initially be approved for central vascular access, a $1B market in the U.S. alone.

NAVAN Technologies, Inc. is an enabling technology company commercializing a novel non-viral delivery platform to radically accelerate genetic engineering of human primary cells. The Nanostraw technology, exclusively licensed from Stanford University, provides direct intracellular access into hard-to-transfect primary human cells for efficient delivery of any cargo. By using a physical, non-perturbative mechanism for delivery, the challenges of viral-based cell manufacturing (time, cost and technical difficulties) are eliminated, resulting in fewer, faster operational steps.
|
Founded in 2017, JuneBrain, LLC is an early start-up company based in the Washington, DC area. Partnering with Johns Hopkins University and Stanford University, our mission is to develop a wearable and non-invasive imaging device that enables multiple sclerosis patients to monitor their disease activity at home, leading to earlier detection of MS attacks and improved monitoring of treatment efficacy. |

https://childrensnational.org/
With a health care experience designed around kids’ unique needs, we’re the premier provider of pediatric services in the Washington, D.C., metro area and its only health system specializing in kids.

Cartesian Therapeutics is a clinical-stage biotechnology company developing novel cellular immunotherapies to cure cancer. Cartesian’s proprietary technology, originally developed by NIH researchers, has the potential to greatly broaden the use of Chimeric Antigen Receptor (CAR) cells for patients with multiple myeloma and other diseases.

Antidote is a digital health company on a mission. Our aim is to accelerate breakthroughs in potentially life-saving treatments by bridging the gap between medical research and the people who need it. “In a world where 80% of clinical trials are delayed or closed due to lack of awareness, we use cutting-edge technology to match the right patients with the right trials. We’re helping medical researchers make progress, faster – and offering new treatment options to patients in need.”


